Martin Wilson, General Counsel of Rocket Pharmaceuticals, Inc., filed a Form 4 on November 17, 2026, disclosing the sale of 4,087 shares of common stock on November 13, 2026, to cover tax withholding obligations related to the vesting of restricted stock units.

Key Highlights

  • Reporting person: Martin Wilson, General Counsel of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
  • Transaction date: November 13, 2026
  • Shares sold: 4,087 shares of common stock, disposed of (Code S)
  • Sale price: $2.25 per share
  • Purpose: According to the filing, shares were sold "in order to pay tax withholding obligations in connection with the vesting of RSUs"
  • Beneficial ownership following transaction: 541,013 shares held directly, including RSUs that convert to common stock on a one-for-one basis

Wilson's RSU Vesting Triggers Tax-Related Share Sale at Rocket Pharmaceuticals

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 17, 2026, Martin Wilson, who serves as General Counsel of Rocket Pharmaceuticals, Inc., disposed of 4,087 shares of the company's common stock on November 13, 2026, at a price of $2.25 per share. The filing reports the transaction under Code S, indicating an open-market sale.

The filing states that the shares were sold by the reporting person "in order to pay tax withholding obligations in connection with the vesting of RSUs." This type of transaction, commonly referred to as a sell-to-cover arrangement, is initiated to satisfy tax obligations that arise when restricted stock units vest, rather than representing a discretionary market sale. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan.

Following the reported transaction, Wilson is listed as directly beneficially owning 541,013 shares of Rocket Pharmaceuticals common stock. The filing notes that this holdings figure includes restricted stock units that convert to common stock on a one-for-one basis. Wilson signed the filing on November 17, 2026, the same date it was submitted to the SEC.

What Was Disclosed

Rocket Pharmaceuticals General Counsel Martin Wilson reported the sale of 4,087 common shares at $2.25 on November 13, 2026, solely to cover RSU vesting tax obligations, leaving him with direct beneficial ownership of 541,013 shares, including RSUs.